GlassScriptPhysician profile
Aaron Robert Noll
NPI 1841641685
$8,680.74
in general payments reported to CMS, 2019-2025
33 companies · $1,446 in 2025
The $1,446 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $472 · 2021: $749 · 2022: $958 · 2023: $1,844 · 2024: $2,360 · 2025: $1,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,442 · Long Term Medical Supply Or Device Loan: $1,208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,442.15 |
| Long Term Medical Supply Or Device Loan | $1,208.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $1,409.88 | 2023-2024 | Iolmaster 700, Quatera 700 |
| Alcon Vision LLC | $1,213.17 | 2019-2025 | Centurion, Clareon, Hydrus Microstent |
| Johnson & Johnson Surgical Vision, INC. | $1,175.08 | 2019-2025 | Tecnis Iol, Veritas Vision System, Tecnis Simplicity |
| Abbvie INC. | $661.40 | 2022-2025 | |
| Biotissue Holdings INC. | $649.58 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $278.43 | 2019-2021 | |
| New World Medical,INC. | $275.24 | 2022-2025 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Rxsight INC | $249.08 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Eyevance Pharmaceuticals LLC | $233.32 | 2022 | |
| Bausch & Lomb Americas INC. | $205.03 | 2023-2025 | Ic-8 Apthera Iol, Envista Mx60 Iol, Totalvisc |
| Sight Sciences, INC. | $194.09 | 2019-2025 | Omni Surgical System |
| Allergan, INC. | $193.06 | 2020-2021 | |
| Ivantis, INC | $191.62 | 2021 | |
| Sun Pharmaceutical Industries INC. | $163.73 | 2021-2024 | Cequa |
| Harrow Eye, LLC | $149.80 | 2025 | Vevye |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Notal Vision, INC. | $145.80 | 2022 | |
| Glaukos Corporation | $140.68 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $132.63 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $132.51 | 2021 | |
| Halozyme INC | $118.42 | 2023-2025 | Hylenex Recombinant |
| Dompe US, INC. | $111.65 | 2025 | Oxervate |
| Amgen INC. | $105.88 | 2024-2025 | Tepezza |
| Oyster Point Pharma, INC. | $102.41 | 2022-2025 | Tyrvaya, Ryzumvi |
| Spark Therapeutics, INC. | $85.82 | 2019 | |
| Ani Pharmaceuticals, INC. | $62.21 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $61.00 | 2024 | Acthar |
| Novartis Pharmaceuticals Corporation | $55.60 | 2021-2023 | |
| Alimera Sciences, INC. | $37.97 | 2021-2024 | Iluvien, Yutiq |
| Regeneron Healthcare Solutions, INC. | $35.32 | 2024 | Eylea Hd |
| Astellas Pharma US INC | $33.66 | 2024 | Izervay |
| Horizon Therapeutics Plc | $33.43 | 2023 | Tepezza |
| Apellis Pharmaceuticals, INC. | $23.02 | 2025 | Syfovre |
| Aerie Pharmaceuticals, INC. | $20.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Noll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.